Related to Banyan Gets $26.3M to Develop Point-of-Care Diagnostic for Brain Injury

• Sutent—Would Biomarkers Have Helped?
  Recent failures bear out the necessity for marker development alongside drug R&D but also highlight the complexities.
  
• Clinical Trial Failures Further Signal Pancreatic Cancer’s Intractable Nature
  Researchers need to step out of the gemcitabine box and also take on the development of diagnostics for early detection.
  
• Advancing Stem Cell Therapies for Multiple Sclerosis
  UKSCF partners with MS Society to financially support clinical development.
  
• Examining Both Sides of the Sirtuin Coin
  Jury is still out on whether inhibition and/or activation can treat neurodegenerative disorders.
  
• Biomarkers Poised for Breakout Moment
  A passel of discussions at BIO highlight the importance of these disease-state indicators.
  
• No New Parkinson Disease Drug Expected Anytime Soon
  Drugs acting on nondopaminergic systems have yet to prove their mettle in clinical trials.
  
• Amgen’s Biomarker Research Underlies Vectibix’ Success
  Next-generation sequencing technology is being used on Phase III trial data.
  
• Getting Personal: Multigene Testing for Individual Cancer Evaluation
  Scientists find comfort in numbers, using molecular patterns as prognostic markers.
  
• Beckman Coulter on the Chopping Block?
  Some analysts believe it is not a question of who will buy the firm but if the firm will be bought.
  
• 2011 Budget Outlook: Trim, Cut, Then Slash
  Agencies like the FDA and NIH are looking at potentially huge cuts.
  
• Tumor Cells Back in Circulation for Monitoring Cancer
  With one test on the market, researchers are developing tools that leverage CTCs as biomarkers.
  
• Study Finds a Friend at NIH but Will Congress Share the Love?
  Paper in NEJM tries to make case for boosting federal research funding amid House leaders’ pursuit of spending cuts.
  
• NIH Updates Its Strategy to Combat Obesity
  Research spending has been on the upswing, but so has the obesity epidemic.